Phase 1/2 Study of Dinutuximab/Cyclophosphamide/Topotecan/Sargramostim (GM-CSF) With or Without Iberdomide in Children With Relapsed, Refractory, or Progressive Neuroblastoma Following Prior Chemoimmunotherapy

This phase I/II trial studies the side effects and best dose of iberdomide when given together with chemoimmunotherapy drugs and to see how well it works in treating patients with neuroblastoma that has come back after a period of improvement (relapsed), that does not respond to treatment (refractory), or that is growing, spreading, or getting worse (progressive) following prior chemoimmunotherapy. Iberdomide is a cereblon-modulating agent. It works by helping the immune system kill tumor cells. Chemoimmunotherapy is chemotherapy combined with immunotherapy. Chemotherapy drugs, such as cyclophosphamide and topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with dinutuximab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Granulocyte-macrophage colony-stimulating factors (GM-CSF), such as sargramostim, may increase the production of blood cells and may help the immune system recover from the side effects of chemotherapy. Giving iberdomide with chemoimmunotherapy may be safe, tolerable, and/or effective in treating patients with relapsed, refractory, or progressive neuroblastoma following prior chemoimmunotherapy.

开始日期2026-10-28

申办/合作机构

National Cancer Institute

NCT07601100

/ Not yet recruiting临床1/2期IIT

A Phase 1b/2 Study of the Combination Isatuximab, Iberdomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible or Not Intended for Upfront Transplant

This study is to evaluate the combination of isatuximab, iberdomide, bortezomib, and dexamethasone in newly diagnosed multiple myeloma participants who are transplant ineligible or not intended for upfront transplant.
The names of the study drugs used in this research study are:
isatuximab, iberdomide, bortezomib dexamethasone

开始日期2026-09-03

申办/合作机构

Dana-Farber Cancer Institute, Inc.

NCT07624513

/ Not yet recruiting临床3期IIT

Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma (NDMM)

The purpose of the study is to determine the best treatment approach based on the risk profile of the cancer cells and on how the disease responds to treatment. This is a randomized research study evaluating treatment for transplant-eligible participants with newly diagnosed multiple myeloma (NDMM). Induction therapy in this study includes the drugs isatuximab, iberdomide, bortezomib, and dexamethasone. After induction therapy, participants will receive consolidation and maintenance therapy that is adapted based on their risk profile and response to treatment.
The research study procedures include: screening for eligibility, study visits, blood and bone marrow tests, disease assessments, treatment with study drugs, and follow-up visits.
It is expected that about 720 participants will take part in this study.

开始日期2026-08-24

申办/合作机构

Dana-Farber Cancer Institute, Inc.

[+4]

100 项与盐酸艾泊度胺相关的临床结果

登录后查看更多信息

100 项与盐酸艾泊度胺相关的转化医学

登录后查看更多信息

100 项与盐酸艾泊度胺相关的专利（医药）

登录后查看更多信息

项与盐酸艾泊度胺相关的文献（医药）

2026-06-05·JOURNAL OF PROTEOME RESEARCH

Ultrahigh-Throughput Liquid Chromatography with Tandem Mass Spectrometry Method for Targeted Protein Degradation Compound Screening Using the Orbitrap Astral Mass Spectrometer

Article

作者: Yang, Yen-Yu ; Maity, Sudipa ; Sun, Qingyu ; Lin, Hanfeng ; Wang, Jin

Targeted protein degradation (TPD) is a therapeutic strategy that utilizes small molecules to induce the proximity-driven degradation of disease-causing proteins. Because the efficacy and selectivity of TPD compounds must be validated across thousands of proteins, high-throughput proteomics is essential for the rapid screening and characterization of these novel degraders. Here, we developed a 300 samples per day (SPD) LC-MS/MS method using the Orbitrap Astral mass spectrometer for ultrahigh-throughput TPD compound screening. We identified close to 8000 protein groups from a single cell line with a coefficient of variation (CV) of less than 10%, highlighting the deep proteome coverage and method reproducibility even at 300 SPD. This high degree of precision provides the statistical confidence to detect subtle, yet significant, changes in protein abundance that were previously challenging to quantify in high-throughput workflows. To evaluate the quantitation accuracy of this method, we further mixed the digests from two or three species at different ratios. Our three-proteome mixture results demonstrated highly accurate quantitation for proteins with both small and large fold changes. Moreover, our two-proteome mixture experiment, where 20 to 160 ng of yeast digest was spiked into 200 ng of HeLa digest, showed an R² of 0.999 for the yeast proteome, underscoring the quantitation accuracy of the method. Utilizing this workflow, we studied dose-dependent protein degradation patterns induced by pomalidomide, iberdomide, and mezigdomide. Our results indicate that mezigdomide may possess enhanced efficacy in T cells by degrading additional proteins such as IKZF2, thereby boosting anticancer immunity. Together, we developed an ultrahigh-throughput LC-MS/MS method with excellent proteome coverage and quantitation accuracy that is highly suitable for chemoproteomics screening of drug libraries.

2026-04-29·INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Genetic Polymorphisms in Systemic Lupus Erythematosus and Their Clinical Implications: A Narrative Review.

Review

作者: Johdi, Nor Adzimah ; Azizan, Elena Aisha ; Rajalingham, Sakthiswary ; Mohd, Rozita ; Egan, Audrey Matilda ; Shaharir, Syahrul Sazliyana ; Zailani, Mohamed Afiq Hidayat

Systemic lupus erythematosus (SLE) is a polygenic autoimmune disorder where genetic diversity drives significant clinical heterogeneity. This review summarizes the current understanding of the roles of genetic polymorphisms in immunological dysregulation, organ-specific manifestations and therapeutic response heterogeneity in individuals with SLE. The literature was obtained from PubMed, EBSCOhost, Web of Science and Scopus. The narrative review comprised 60 publications published within the last 12 years. The research consistently identifies the major histocompatibility complex (MHC) region as the most significant genetic risk factor for the onset of autoimmunity. Genetic variants in STAT4 and IRF5 exacerbate disease progression by facilitating chronic inflammation. These genetic factors are associated with various clinical outcomes, including renal and neuropsychiatric symptoms. Polymorphisms in HLA class II, TLR7 and FBN2 are notably linked to serious consequences, including lupus nephritis (LN). Progress in targeted therapy signifies a transition to personalized medicine with medications such as anifrolumab, litifilimab, iberdomide and Janus kinase (JAK) or Cyclin-Dependent Kinase (CDK) inhibitors, demonstrating potential for targeting pathways associated with the interferon gene signature and STAT4 polymorphisms. Notwithstanding the problems presented by the heterogeneity of SLE, the identification of risk variations is anticipated to enhance predictive and therapeutic biomarkers, hence facilitating more precise and individualized disease management.

2026-01-01·Lancet Haematology

Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial

Article

作者: Roeloffzen, Wilfried W H ; Verkleij, Christie P M ; de Ruijter, Maaike E M ; Wegman, Jurgen ; Zweegman, Sonja ; Nijhof, Inger S ; Smits, Febe ; de Weerdt, Okke ; Nasserinejad, Kazem ; Kerstiens, Ramses ; Smit, Nina ; Franssen, Laurens E ; Mutis, Tuna ; de Kort, Elizabeth A ; Korst, Charlotte L B M ; Croockewit, Alexandra J ; van de Donk, Niels W C J ; Levin, Mark-David ; Plattel, Wouter ; van der Spek, Ellen ; van der Klift, Marjolein ; Groen, Kaz ; Westerman, Matthijs

BACKGROUND:

Iberdomide is an oral cereblon E3 ligase modulator with higher affinity to cereblon than immunomodulatory drugs, leading to improved direct anti-myeloma activity and enhanced immunostimulatory effects. We aimed to evaluate the safety and activity of iberdomide plus low-dose cyclophosphamide and dexamethasone (IberCd) in patients with relapsed and refractory multiple myeloma.

METHODS:

The ICON study is a prospective, single-arm, phase 2, open-label study conducted in eight hospitals in the Netherlands. We enrolled patients (aged ≥18 years) with relapsed and refractory multiple myeloma (lenalidomide-refractory) who had received two to four previous lines of therapy and had a WHO performance status of 0-2. Patients were treated with oral iberdomide (1·6 mg/day on days 1-21 of each 28-day cycle), oral low-dose cyclophosphamide (50 mg/day on days 1-28), and oral dexamethasone (40 mg [20 mg in patients age >75 years] once a week) until progression. All patients received thrombosis prophylaxis daily: 80 mg oral aspirin or 100 mg oral carbasalate calcium. Patients with a previous history of venous thromboembolism received only low molecular-weight heparin by subcutaneous injection. The primary endpoint was progression-free survival, defined as time from the start of treatment to the date of progression or death. Activity and safety were assessed in all patients who started treatment. This trial was registered at ClinicalTrials.gov (NCT04392037) and is ongoing.

FINDINGS:

Between Feb 17, 2021, and July 7, 2023, 61 patients were enrolled and received IberCd treatment (29 [48%] were female and 32 [52%] patients were male). The median number of previous lines of therapy was 3 (range 2-5); 52 (85%) patients were triple-class exposed and 27 (44%) had triple-class refractory disease. 50 patients discontinued study treatment, 39 of whom due to progressive disease, but all 61 patients were included in the main analysis population. After a median follow-up of 25·4 months (IQR 19·7-31·6), the median progression-free survival was 17·6 months (one-sided 95% CI 16·6-19·9). In all 61 patients, the most common grade 3-4 adverse events were neutropenia (34 [56%] patients) and infections (21 [34%] patients). Treatment-related serious adverse events were reported in 25 (41%) patients, with infections being the most common (34 [71%] of 48 serious adverse events). Treatment-related death occurred in one (2%) patient due to COVID-19.

INTERPRETATION:

IberCd is an all-oral and active combination for patients with relapsed and refractory multiple myeloma that showed clinically meaningful activity. This regimen offers a valuable treatment option for patients who have received two to four previous lines of therapy and compares favourably with other available treatments.

FUNDING:

Bristol Myers Squibb.

622

项与盐酸艾泊度胺相关的新闻（医药）

2026-10-07

·观行研习社

行业动态信息 | 2026年10月第1周（9.30-10.6）

行业动态信息观行研习社 · 本周医药圈要闻一览（2026年10月第1周 9.30-10.6）日期行业新闻 9月30日十部门联合印发《医药工业发展“十五五”规划》，明确2030年规模以上药企营收超3.5万亿元、首创药（FIC）占全球比例≥25%、创新药产业年均增速≥20%。（工信部/人民日报） 9月30日国家药监局附条件批准盐酸艾泊度胺胶囊上市，系全球首个CELMoD类口服药、首个以MRD阴性完全缓解为中间终点获批的复发/难治多发性骨髓瘤药物。（国家药监局） 9月30日诺诚健华与礼来达成研发合作及授权许可，含最高1亿美元首付款、总规模可达32.5亿美元，依托自有平台共同开发最多5个创新靶点项目。（上海证券报） 9月30日百利天恒多款自研ADC密集获突破性治疗品种认定，宜泽康（伦康依隆妥单抗）新增胆道癌适应症，并触发与百时美施贵宝合作项下第二笔2.5亿美元付款。（上海证券报） 9月30日湖南出台促进生物医药产业创新发展若干意见，新获批国家级科技创新中心每年一次性奖补500万元、连续3年，地方创新药扶持“真金白银”化。（湘政办发〔2026〕15号） 10月1日《医疗机构麻醉药品和精神药品管理规定》正式施行，第二类精神药品（含艾司唑仑、唑吡坦等安眠药）纳入全流程严格管理，互联网诊疗被禁止开具麻精药品处方。（国家卫健委） 10月1日市场监管总局公布“破除统一大市场卡点堵点”专项行动第二批案件，湖北卫健委擅自制定“药品鼓励应用目录”（26种本地药品）被查处，滥用行政权力排除限制竞争。（法治日报） 10月1日奥啡类物质整类列入《非药用类麻醉药品和精神药品目录》，对溴啡、螺溴啡衍生物实施整类列管，新精神活性物质监管加码。（公安部/药监局） 10月1日 7家中药饮片企业因违规被直接取消集采中选资格，凸显集采“违规即出局”的刚性约束。（中国经济网） 10月2日国家医保局数据显示抗肿瘤药销售金额中创新药占比已从27%升至53%，官方口径确认创新药进入医保落地放量、商业化兑现期。（国家医保局） 9月28日-10月2日国产创新药BD出海集中爆发：迪哲医药收到阿斯利康6亿美元首付款（舒沃哲全球授权，另有最高9亿美元里程碑）、恒瑞GLP-1/GIP双靶点HRS-1596授权诺和最高26亿美元、康方依沃西联合阿斯利康获20亿美元战略合作、默沙东-思璞锐KRAS G12D全球授权最高21.3亿美元，单笔均破20亿美元。（央广网） 10月2日艾博生物mRNA编码CD19×CD3双靶点TCE药物ABO2203授权诺华，潜在总额约77.75亿美元，创国内mRNA对外授权新高。（央广网） 10月3日广州医保依托“药品追溯码”大数据模型打掉司美格鲁肽“回流药”犯罪团伙，本该冷链保存的药品在高温常温散放后被伪装冷链转售，查扣8000余盒。（央视新闻） 10月3日人民日报客户端发文警示“AI假医生”批量生成带货乱象，医生形象被AI批量生成滥用，动摇社会对医学专业的信任根基。（人民日报客户端） 10月4日翰森制药奥莱泊肽（双偏向型GLP-1/GIP受体激动剂）Ⅲ期48周平均减重19.3%、胃肠道不良事件率低于同类，入选EASD突破性摘要。（央广网） 10月4日合肥天港医诺pH选择性条件激活T细胞衔接器TGI-10获批临床，针对全新药物靶点，系全球同靶点潜在“同类第一”。（合肥日报） 10月5日《药品管理法》启动系统性“大修”，围绕“鼓励新药研制、加强生产销售管理、强化药价监管”修改条文，明确假药劣药范围。（全国人大网） 10月5日海南审结首例药品专利纠纷早期解决机制行政裁决案，40天线上结案，明确仿制药报送集采、申请挂网即便事后撤回仍可能构成“许诺销售”侵权。（南方+） 10月6日央视《每周质量报告》再点名“AI医生形象带货卖药”乱象，明确“医务人员形象不得用于商业医疗广告，AI披白大褂须前置核验资质”。（央视网） 10月6日传奇生物任命诺华前中国总裁张颖为新任CEO（9月15日生效），其CARVYKTI（西达基奥仑赛）Q2净销售额6.57亿美元、单季净利扭亏。（传奇生物）以上为本周（9.30-10.6）行业新闻罗列。

引进/卖出抗体药物偶联物信使RNA

2026-10-05

·大Ro姐

20261005 医药行业日报

🎨 今日漫画图解｜ATL-101 如何「沉默」亨廷顿致病基因：鞘内注射二价 siRNA，锁住 HTT 的信使 RNA，让有毒蛋白不再被生产（一句话看懂基因沉默机制） 📅 20261005 医药行业日报（每日速览 · 过敏 / 神经 / 政策） 🔴 过敏速览 1) 新加坡国立大学医院启动全球首批虾/贝类过敏口服免疫疗法（OIT）临床试验：用微量虾粉「训练… 新加坡国立大学医院（NUH）于 10 月初启动该国首个、也是本区域最早的虾过敏口服免疫疗法（OIT）临床试验，计划招募约 30 名参与者（20 人治疗组、10 人对照），在医疗监督下服用剂量逐步递增的特制虾粉、为期 8–10 个月，并随访长来源 · Channel NewsAsia / 8视界（2026-10-02 报道）；NUH 临床研究 🔗 https://www.8world.com/singapore/first-trial-oral-immunotherapy-for-prawn-allergy-3297496 2) EP-104GI 局部食管壁给药治嗜酸细胞性食管炎（EoE）：单次给药、52 周 64% … EP-104GI 是一款直接注射到食管壁局部的治疗药物（非全身生物制剂），用于嗜酸细胞性食管炎（EoE，一种与 2 型炎症相关的食管过敏/嗜酸疾病，表现为吞咽困难、食物卡喉）。来源 · BioPharmCatalyst Weekly Watchlist（2026-10-02 更新；数据 2026-09-30 披露） 🔗 https://www.biopharmcatalyst.com/news/2026/october-2-2026-biopharmcatalyst-weekly-watchlist-key-phase-1-2-catalysts-for-the-next-6-months 3) 赛诺菲/再生元扩展全球免疫学抗体联盟，押注多款「更长间隔」下一代长效品种（dupixent… 10 月 1 日，赛诺菲与再生元宣布扩展双方全球免疫学抗体联盟，新增多款处于研发阶段、主打「更长给药间隔」的下一代长效免疫学抗体资产，覆盖特应性皮炎、哮喘等 2 型炎症疾病——本质是为年销售额领先的度普利尤单抗（dupixent，抗 IL- 来源 · 赛诺菲 / 再生元官方新闻稿（2026-10-01 公布）；1st Oncology 转述 🔗 https://www.1stoncology.com/blog/sanofiregeneron-expand-global-alliance-with-multiple-next-generation-long-acting-immunology-antibodies1234671216 💡 过敏一句话今天过敏线讲了三件「和食物/食管有关的过敏新进展」，主线是：不把免疫系统一棍子打死，而是用更巧的办法重建耐受或精准局部压制。第一条，虾/贝类过敏在新加坡启动了首个口服免疫疗法（OIT）临床试验——简单说就是「一点点、一点点地喂虾粉，让身体学会不再大惊小怪」。 🔵 神经速览 1) Atlanta 的 ATL-101（二价小干扰 RNA，靶向 HTT 基因）鞘内注射治亨廷… Atalanta Therapeutics 申报的 1 类新药 ATL-101 鞘内注射液本周在中国首次获临床试验默示许可，拟用于亨廷顿病（HD）成人患者。来源 · 医药观澜 / CDE、合肥日报（2026-10-03 梳理；9-28~10-03 获批临床） 🔗 https://www.163.com/dy/article/L8ALE2SK05568W0A.html 2) BMS-986446（抗 MTBR-tau 抗体）获 FDA 快速通道，早期阿尔茨海默病：… 百时美施贵宝（BMS）的 BMS-986446 获 FDA 快速通道认定，这是一款处于 II 期、潜在「best-in-class」的抗 tau 单克隆抗体，靶向 tau 蛋白的微管结合区（MTBR），用于早期阿尔茨海默病（AD）。来源 · Psychiatric Times《October in Review》（2026-10 精神科管线更新） 🔗 http://www.psychiatrictimes.com/view/october-in-review-updates-on-the-psychiatric-treatment-pipeline/ 3) LB-102（D2/D3/5-HT7 选择性拮抗，苯丙胺磺酸盐衍生物）精神分裂症 II 期… LB Pharmaceuticals 在 2026 年 SIRS 年会上公布 LB-102 的 II 期 NOVA-1 试验亚组分析：这款每日一次口服小分子、选择性拮抗多巴胺 D2/D3 与 5-HT7 受体，在精神分裂症中不仅总体症状显著来源 · Psychiatric Times（2026 精神分裂症国际研究学会年会 SIRS 报道；NOVA-1 亚组分析） 🔗 https://psychiatrictimes.com/view/phase-2-trial-of-lb-102-for-schizophrenia-shows-positive-impact-on-cognitive-performance 🟢 政策速览 1) 第二批全国中药饮片联采即将落地执行：北京 10-31、云南 10-20 起，中药饮片纳入集… 继中成药之后，全国中药饮片采购联盟集中采购第二批结果进入执行阶段：北京市明确 10 月 31 日 0 时起全面执行带量采购中选结果、10 月 24 日起可调价备货；云南省将于 10 月 20 日起执行、采购周期原则上 1 年。来源 · 北京市医疗保障局 / 云南省医疗保障局（2026-09-30、10 月通知；2026-10 执行） 🔗 https://ybj.beijing.gov.cn/zczxs/2020_ycgga/202609/t20260930_4887633.html 2) NMPA 附条件批准 BMS 艾泊度胺（mezigdomide，口服 CELMoD/cer… 9 月 30 日，国家药监局通过优先审评、附条件批准百时美施贵宝 1 类创新药盐酸艾泊度胺胶囊（赞赋，mezigdomide）上市，联合达雷妥尤单抗+地塞米松，用于既往至少接受过一线（含一种蛋白酶体抑制剂和一种免疫调节剂）治疗的多发性骨髓瘤来源 · 国家药监局 / 中国食品药品网（2026-09-30 批准；智慧芽新药情报库转述） 🔗 https://synapse.zhihuiya.com/organization/c41232f188f070d7c44795cde72e3cc6 3) 本周 12 款 1 类新药在中国获批临床：覆盖亨廷顿病 siRNA、TCE 抗体、同种异体… 据 CDE 官网及公开资料梳理，9 月 28 日至 10 月 3 日当周共有 12 款 1 类创新药首次在中国获临床试验默示许可，涵盖小分子、抗体、寡核苷酸疗法与细胞疗法等多技术路线：Atalanta 的 ATL-101（二价 siRNA，来源 · 医药观澜 / CDE 官网（2026-10-03 梳理；9-28~10-03 获批 IND） 🔗 https://www.163.com/dy/article/L8ALE2SK05568W0A.html 📖 二价小干扰 RNA（di-siRNA）与「基因沉默」小干扰 RNA（siRNA）是一类能「精确关闭某个基因」的短双链 RNA：它进入细胞后会搭上 RISC 复合体，专门去找与自己序列匹配的「信使 RNA（mRNA）」——也就是基因翻译成蛋白质的「中间图纸」，把它降解掉，于是这个基因就「沉默」、不再产出有害蛋白。 — AI 自动生成 · 数据来自公开报道 · 仅供行业交流 —

免疫疗法siRNA

2026-10-05

·搜狐新闻

恒瑞26亿美元授权诺和诺德创新药出海热

9月底到10月初，中国创新药出海迎来一波密集兑现，跨国药企在三天内连下三单，把中国管线推上全球舞台中央。最重磅的是恒瑞医药。9月29日，恒瑞宣布与诺和诺德达成独家许可协议，将每周一次口服GLP-1/GIP双靶点药物HRS-1596的大中华区外全球权益授权给对方，首付款3亿美元，潜在总额最高26亿美元。一款国产减肥降糖药能被全球糖尿病巨头反向抄底，本身就是中国创新药研发实力被国际认可的信号。石药集团同样动作频频。9月28日至29日，其mRNA肿瘤疫苗SYS6077获批临床、重组带状疱疹疫苗SYS6052获美国FDA临床许可、减重药JMT206进入Ib期，年内已有15款1类新药获批临床，研发管线进入密集兑现期。更大的手笔在10月2日：艾博生物宣布授予诺华mRNA药物ABO2203的全球独家许可权，首付款5.75亿美元，潜在里程碑最高约72亿美元，这是诺华在自身免疫领域对中国mRNA技术的大手笔押注。据观察者网梳理，默沙东、诺和诺德、阿斯利康三天内合计出手三单，潜在金额超67亿美元、首付款超9亿美元。与此同时，BMS的盐酸艾泊度胺胶囊9月30日在中国获批上市，再生元10月1日公布GDF-8抗体与司美格鲁肽联用可显著减少减重的肌肉流失。一周之内，跨国药企狂扫中国管线，说明中国创新资产的差异化靶点和商业化能力正被全球重新定价。对投资者而言，创新药板块供给端在快速扩容，但个股分化极大——真正有全球竞争力的公司，才配得上长线关注。对普通投资者来说，不必追着每一笔授权去炒概念，但可以借这股出海浪潮，重新审视那些有真研发、真管线的中国药企——它们的价值，正在被全球资本重新发现。返回搜狐，查看更多

引进/卖出疫苗临床1期信使RNA快速通道

100 项与盐酸艾泊度胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11134	-	-	DB12101

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
多发性骨髓瘤	美国	Bristol Myers Squibb Co.	2026-08-13

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
难治性多发性骨髓瘤	临床2期	美国	Bristol Myers Squibb Co.	2024-02-20
复发性多发性骨髓瘤	临床2期	美国	Bristol Myers Squibb Co.	2024-02-20
侵袭性 B 细胞非霍奇金淋巴瘤	临床2期	美国	Celgene Corp.	2021-10-10
侵袭性 B 细胞非霍奇金淋巴瘤	临床2期	奥地利	Celgene Corp.	2021-10-10
侵袭性 B 细胞非霍奇金淋巴瘤	临床2期	比利时	Celgene Corp.	2021-10-10
侵袭性 B 细胞非霍奇金淋巴瘤	临床2期	法国	Celgene Corp.	2021-10-10
侵袭性 B 细胞非霍奇金淋巴瘤	临床2期	韩国	Celgene Corp.	2021-10-10
侵袭性 B 细胞非霍奇金淋巴瘤	临床2期	西班牙	Celgene Corp.	2021-10-10
侵袭性 B 细胞非霍奇金淋巴瘤	临床2期	中国台湾	Celgene Corp.	2021-10-10
侵袭性 B 细胞非霍奇金淋巴瘤	临床2期	英国	Celgene Corp.	2021-10-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05177536 (ASCO2026)	临床2期	多发性骨髓瘤维持	38	Iberdomide 1.0 mg	夢淵鑰遞衊鏇憲簾蓋築(鹽餘鹹淵網網鹽築簾選) = 選艱構繭範簾廠鹽壓築齋餘製鹽廠選齋鏇餘糧 (艱範窪醖憲繭廠構顧鬱 ) 更多	积极	2026-05-29
NCT05392946 (IDEAL, ASCO2026)	临床1/2期	多发性骨髓瘤	47	BortezomibDaratumumabIberdomide + BortezomibDaratumumabIberdomideb + BortezomibDaratumumabIberdomide + BortezomibDaratumumabIberdomideone	製鬱鑰顧壓構築窪繭範(醖鏇鑰醖衊廠艱糧製壓) = DLT (all grade 4 neutropenia) was noted in 3 pts, 2 at DL 1 & 1 at DL -1 鹹繭積餘淵鑰齋齋窪淵 (膚窪壓襯範選遞膚選窪 )	积极	2026-05-29
NCT02773030 (CC-220-MM-001, EHA2026)	临床1/2期	多发性骨髓瘤一线	75	Iberdomide plus daratumumab and dexamethasone	艱襯壓衊廠鹹製糧網製(膚構艱淵簾淵築築顧製) = 網餘醖獵餘鬱構製繭顧網鹽壓鏇簾願夢繭選簾 (醖壓醖夢構憲壓鑰構構 ) 更多	积极	2026-05-12
NCT02773030 (CC-220-MM-001, EHA2026)	临床1/2期	多发性骨髓瘤一线	75	Iberdomide plus daratumumab and dexamethasone (Baseline CrCl ≥90 mL/min)	艱襯壓衊廠鹹製糧網製(膚構艱淵簾淵築築顧製) = 簾鬱窪繭齋獵鹽製鹽襯網鹽壓鏇簾願夢繭選簾 (醖壓醖夢構憲壓鑰構構 ) 更多	积极	2026-05-12
NCT05354557 (Tandem Meetings ASTCT and CIBMTR2026)	临床2期	多发性骨髓瘤维持	15	Iberdomide 1 mg	願簾鑰窪選積夢窪醖鹹(衊糧願廠窪憲艱獵夢築) = neutropenia (n=1), rash (n=2), and infections (n=3). 襯壓憲選獵齋齋壓鹽鹽 (齋願繭願醖鹽壓網獵鹽 ) 更多	积极	2026-02-04
NCT04392037 (ICON, Pubmed \| Lancet Haematol)	临床2期	复发性多发性骨髓瘤	61	dexamethasonecyclophosphamideIberdomide + dexamethasonecyclophosphamideIberdomidehamide + dexamethasonecyclophosphamideIberdomideone (relapsed and refractory multiple myeloma)	壓醖顧選獵築鹹顧鹹衊(壓餘構餘繭糧衊網衊夢) = 34% of patients experienced infections 衊鏇窪壓繭築齋鏇網憲 (鑰簾鏇鏇夢醖餘襯餘繭 ) 更多	积极	2026-01-01
NCT02773030 (CC-220-MM-001, ASH2025)	临床1/2期	多发性骨髓瘤	75	Iberdomide plus daratumumab and dexamethasone (IberDd)	鑰觸鹹鹽構壓夢鑰衊選(顧繭醖窪膚積鏇夢鹹構) = 糧鬱構衊憲築積築襯範夢鏇願衊繭艱鏇餘願繭 (廠鹽鏇膚積觸憲壓鹹齋 ) 更多	积极	2025-12-06
NCT02773030 (CC-220-MM-001, ASH2025)	临床1/2期	多发性骨髓瘤	75	Iberdomide plus daratumumab and dexamethasone (IberDd) (No renal impairment)	鑰觸鹹鹽構壓夢鑰衊選(顧繭醖窪膚積鏇夢鹹構) = 製壓蓋鑰鏇築膚廠衊壓夢鏇願衊繭艱鏇餘願繭 (廠鹽鏇膚積觸憲壓鹹齋 ) 更多	积极	2025-12-06
NCT05354557 (ASH2025)	临床2期	维持	15	Iberdomide 1 mg	鑰糧壓範顧獵齋鬱鑰鬱(構窪淵蓋衊壓膚齋衊衊) = 醖築鬱淵膚遞願遞鬱齋醖製鏇製簾鏇蓋夢艱繭 (鹹衊夢蓋顧窪襯艱選壓 ) 更多	积极	2025-12-06
NCT05896228 (ReKInDLE, ASH2025)	临床2期	复发性多发性骨髓瘤	30	Iberdomide+Carfilzomib+Daratumumab+Dexamethasone	夢壓衊淵齋鏇廠簾壓蓋(艱顧獵窪遞蓋遞膚齋壓) = Grade 3 or greater events included neutropenia (50%), lymphocytopenia (40%), leukopenia (23%), thrombocytopenia (10%), and anemia (3%) but were manageable with growth factor support and/or iber dose-reduction, as needed. 鬱鏇衊夢觸觸夢憲艱築 (鹽鬱廠齋鹹憲夢廠鏇淵 ) 更多	积极	2025-12-06
ALLG MM25 (ASH2025)	临床1/2期	多发性骨髓瘤 t(11;14)	20	Venetoclax+Iberdomide+dexamethasone	齋壓簾願鹹繭憲觸憲醖(構獵襯選築襯網憲廠淵) = 襯夢顧糧網鬱範願廠觸壓齋構積構夢蓋壓願餘 (夢遞醖鬱鹽夢淵積顧願 ) 更多	积极	2025-12-06
ACTRN12621001037897 (IBIS, ASH2025)	临床1期	多发性骨髓瘤	29	Iberdomide+Isatuximab+Dexamethasone	壓襯願選夢觸範艱窪鏇(遞窪壓網遞築鹽簾餘獵) = 壓鏇蓋鑰窪鹽鹹糧鏇膚夢淵衊築襯築簾糧衊鏇 (鹽觸膚簾鹽顧製選壓鹹, 50.3 ~ 82.6) 更多	积极	2025-12-06